The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) (NASDAQ: TTPH) securities who purchased shares (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13, 2018.
The complaint alleges thatÂ (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial’s primary endpoints ; (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial’s primary endpoints; and (3) consequently, Defendants’ statements about Tetraphase’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
Shareholders have until September 25, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
Please fill out the form to learn more